Monday, October 14

Healthcare

Immunovant stock falls 8% amid Graves' disease program update

09/10/20241 Min Read

disease falls Graves039 Immunovant program stock update

Previous ArticleAstraZeneca reports disappointing Phase 3 data for lung cancer ADC (NASDAQ:AZN)

Next Article Relay Therapeutics announces proposed public offering of common stock